Refocus Group's Mission is to Become a Surgical Standard of Care for Presbyopia, Primary Open-Angle Glaucoma and Ocular Hypertension Worldwide
Welcome to Refocus Group Inc., a medical device company engaged in the research and development of treatments for human vision disorders. Refocus Group owns over 90 domestic and international pending applications and issued patents, the vast majority directed to methods, devices, and systems for the treatment of presbyopia, ocular hypertension, and primary open angle glaucoma.
Please note that the company’s primary product, the PresView™ Scleral Implant, is an investigational device and is not yet approved for sale or use in the United States or Canada. However, the product is currently approved for sale in the European Union. |
|
 |
| PresView™ SSP and Presbyopia |
|
|
 |
| PresView™ SSP and Glaucoma |
|
|
Note: The PresView™ SSP System for Presbyopia is an investigational device and is not yet approved for sale or use in the United States or Canada. The product is currently approved for sale in the European Union.
|
| Note: At this time, the use of the PresView™ SSP System for Glaucoma and Ocular Hyper Tension is only available within the European Union, where clinical trials are currently under way.
|
PresView™ is a registered trademark of Refocus Group, Inc. |
|
|
